Progesterone inhibits human endothelial cell proliferation through a p53-dependent pathway

Cellular and Molecular Life Sciences

Volumn 65, Issue 23, 2008, Pages 3839-3850

  Hsu, S P ^a,b   Ho, P Y ^c   Juan, S H ^b   Liang, Y C ^c   Lee, W S ^b,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Angiogenesis; p21; p27; p53; Progesterone

Indexed keywords

CYCLIN DEPENDENT KINASE 2; DNA; MESSENGER RNA; PROGESTERONE; PROTEIN P21; PROTEIN P27; PROTEIN P53; THYMIDINE;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL;

ANALYSIS OF VARIANCE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COLLAGEN; DNA PRIMERS; DRUG COMBINATIONS; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; LAMININ; NEOVASCULARIZATION, PHYSIOLOGIC; PROGESTERONE; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES; TUMOR SUPPRESSOR PROTEIN P53; UMBILICAL VEINS;

MUS;

EID: 57349131692     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-008-8441-3     Document Type: Article

References (36)

1. Alexandersen, P., Tanko, L. B., Bagger, Y. Z., Qin, G. and Christiansen, C. (2006) The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric 9, 108-118.
2. Koh, K. K., Son, J. W., Ahn, J. Y., Lee, S. K., Hwang, H. Y., Kim, D. S., Jin, D. K., Ahn, T. H. and Shin, E. K. (2001) Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels. Int. J. Cardiol. 81, 43-50.
3. Littleton-Kearney, M. T., Klaus, J. A. and Hurn, P. D. (2005) Effects of combined oral conjugated estrogens and medroxyprogesterone acetate on brain infarction size after experimental stroke in rat. J. Cereb. Blood Flow Metab. 25, 421-426.
4. Tsuda, K., Kinoshita-Shimamoto, Y., Mabuchi, Y. and Nishio, I. (2003) Hormone replacement therapy improves membrane fluidity of erythrocytes in postmenopausal women: an electron paramagnetic resonance investigation. Am. J. Hypertens. 16,502-507.
5. Lee, W. S., Harder, J. A., Yoshizumi, M., Lee, M. E. and Haber, E. (1997) Progesterone inhibits arterial smooth muscle cell proliferation. Nat. Med. 3, 1005-1008.
6. Lee, W. S., Liu, C. W., Juan, S. H., Liang, Y. C., Ho, P. Y. and Lee, Y. H. (2003) Molecular mechanism of progesterone-induced antiproliferation in rat aortic smooth muscle cells. Endocrinology 144, 2785-2790.
7. Vazquez, F., Rodriguez-Manzaneque, J. C., Lydon, J. P., Edwards, D. P., O'Malley, B. W. and Iruela-Arispe, M. L (1999) Progesterone regulates proliferation of endothelial cells. J. Biol. Chem. 274, 2185-2192
8. Papetti, M. and Herman, I. M. (2002) Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol. Cell Physiol. 282, C947-970.
9. Risau W. (1997) Mechanisms of angiogenesis. Nature 386, 671-674.
10. Albrecht, E. D., Aberdeen, G. W., Niklaus, A. L., Babischkin, J. S., Suresch, D. L. and Pepe, G. J. (2003) Acute temporal regulation of vascular endothelial growth/permeability factor expression and endothelial morphology in the baboon endometrium by ovarian steroids. J. Clin. Endocrinol. Metab. 88, 2844-2852.
11. Niklaus, A. L., Aberdeen, G. W., Babischkin, J. S,, Pepe, G. J. and Albrecht, E. D. (2003) Effect of estrogen on vascular endothelial growth/permeability factor expression by glandular epithelial and stromal cells in the baboon endometrium. Biol. Reprod. 68, 1997-2004.
12. Sengupta, K., Banerjee, S., Saxena, N. and Banerjee, S. K. (2003) Estradiol-induced vascular endothelial growth factor-A expression in breast tumor cells is biphasic and regulated by estrogen receptor-alpha dependent pathway. Int. J. Oncol. 22, 609-614.
13. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
14. Bartussek, C., Naumann, U. and Weller, M. (1999) Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status. Exp. Cell. Res. 253, 432-439.
15. Wong, K. B., DeDecker, B. S., Freund, S. M., Proctor, M. R., Bycroft, M. and Fersht, A. R. (1999) Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc. Natl. Acad. Sci. USA 96, 8438-8442.
16. Lin, S. Y., Liu, J. D., Chang, H. C., Yeh, S. D., Lin, C. H. and Lee, W. S. (2002) Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. J. Cell Biochem. 84, 532-544.
17. Lin, S. Y., Liang, Y. C,, Ho, Y. S., Tsai, S. H., Pan, S. and Lee, W. S. (2002) Involvement of both extracellular signal-regulated kinase and c-jun N-terminal kinase pathways in the 12-O-tetradecanoylphorbol-13-acetate-induced upregulation of p21(Cip1) in colon cancer cells. Mol. Carcinog. 35, 21-28.
18. Grant, D. S., Kinsella, J. L., Fridman, R., Auerbach, R., Piasecki, B. A., Yamada, Y., Zain, M. and Kleinman, H. K. (1992) Interaction of endothelial cells with a laminin A chain peptide (SIKVAV) in vitro and induction of angiogenic behavior in vivo. J. Cell Physiol. 53, 614-625.
19. Passaniti, A., Taylor, R. M., Pili, R., Guo, Y., Long, P. V., Haney, J. A,, Pauly, R. R., Grant, D. S. and Martin, G. (1992) A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest; a journal of technical methods and pathology 67, 519-528.
20. Graham, J. D. and Clarke, C. L. (1997) Physiological action of progesterone in target tissues. Endocr. Rev. 18, 502-519.
21. Clarke, C. L. and Sutherland, R. L. (1990) Progestin regulation of cellular proliferation. Endocr. Rev. 11, 266-301.
22. Horwitz, K. B. The molecular biology of RU486. (1992) Is there a role for antiprogestins in the treatment of breast cancer? Endocr. Rev. 13, 146-163.
23. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. and Elledge, S. J. (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816.
24. Toyoshima, H. and Hunter, T. (1994) P27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78, 67-74.
25. Xiong , Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R. and Beach, D. (1993) P21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704.
26. Harper, J. W., Elledge, S. J., Keyomarsi, K., Dynlacht, B., Tsai, L. H., Zhang, P., Dobrowolski, S., Bai, C., Connell-Crowley, L., Swindell, E., Fox, M. P. and Wei. N. (1995) Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 6,387-400.
27. el-Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Canman, C. E., Jackman, J., Pietenpol, J. A., Burrell, M., Hill, D. E., Wang, Y., Wiman, K. G., Wdward Mercer, W., Kastan, M. B., Kohn, K. W., Elledge, S. J., Kinzler, K. W. and Vogelstein, B. (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54, 1169-1174.
28. Chen, J., Jackson, P. K., Kirschner, M. W. and Dutta, A. (1995) Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374, 386-388.
29. Lin, J., Reichner, C., Wu, X. and Levine, A. J. (1996) Analysis of wild-type and mutant p21WAF-1 gene activities. Mol. Cell Biol. 16,1786-1793.
30. Blain, S. W., Montalvo, E. and Massague, J. (1997) Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. J. Biol. Chem. 272, 25863-25872.
31. He, G., Siddik, Z. H., Huang, Z., Wang, R., Koomen, J., Kobayashi, R., Khokhar, A. R. and Kuang, J. (2005) Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene 24, 2929-2943.
32. Igata, M., Motoshima, H., Tsuruzoe, K., Kojima, K., Matsumura, T., Kondo, T., Taguchi, T., Nakamaru, K., Yano, M., Kukidome, D., Matsumoto, K., Toyonaga, T., Asano, T., Nishikawa, T. and Araki, E. (2005) Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ. Res. 97, 837-844.
33. Wright, J. W., Stouffer, R. L. and Rodland, K. D. (2005) High-dose estrogen and clinical selective estrogen receptor modulators induce growth arrest, p21, and p53 in primate ovarian surface epithelial cells. J. Clin. Endocrinol. Metab. 90, 3688-3695.
34. Tong, W. and Pollard, J. W. (1999) Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice. Mol. Cell Biol. 19, 2251-2264.
35. Swarbrick, A., Lee, C. S,, Sutherland, R. L. and Musgrove, E. A. (2000) Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol. Cell Biol. 20, 2581-2591.
36. Owen, G. I., Richer, J. K., Tung, L., Takimoto, G. and Horwitz, K. B. (1998) Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. J. Biol. Chem. 273, 10696-10701.